EP#87: Ioannis Gkouzionis, Co-Founder and CEO of Aisthesis Medical

Published on May 22, 2024

In today’s.episode, we are.thrilled to welcome.Ioannis Gkouzionis from.Aisthesis Medical, leading the charge in acute care transformation with their pioneering AI technology. Their flagship product, VIOSync,.is an AI-powered clinical.decision-support system designed to predict.and prevent critical health risks.like sepsis and organ failure, ultimately enhancing patient outcomes and streamlining healthcare processes. Seamlessly integrating with various medical devices, VIOSync creates personalized.digital profiles for each patient, revolutionizing.the way healthcare is delivered.

 

ℹ️ Ioannis is originally from Thessaloniki, Greece, and is an alumnus of the.Technical University of Crete, where he earned both his MEng (2017) and MSc (2019) in Electrical and Computer Engineering, focusing on.Machine Learning in medical imaging. His journey continued.with a PhD in Clinical Medicine Research at the.Hamlyn Centre for Robotic Surgery, Imperial College London, culminating in the development of a pioneering AI-based surgical imaging guidance.system for gastrointestinal cancer surgery. Having completed my PhD (2023), he has transitioned.into entrepreneurship as.the Co-founder and CEO of Aisthesis Medical, a MedTech startup.dedicated to revolutionising acute care through XAI-driven clinical decision-support.for sepsis prediction and multi-organ failure prevention. His commitment to transforming medical devices into.clinical solutions was.recognised.when he was featured in the.Forbes 30 Under 30 Greece list for 2023.

Timestamps

    00:00 introduction

    01:00 Ioannis’s background

    03:09 Problems that Aisthesis Medical addresses

    06:33 What is a digital patient twin?

    08:30 Ideal Customer

    10:57 Aisthesis Medical’s Journey

    14:13 Marketplace Competition

    20:50 Clinical Trial

    22:38 The Patent

    27:44 Funding

    29:40 Aisthesis Medical’s Team

    33:00 Biggest challenges in the next growth phase

    35:25 Closing words

Stay up-to-date with exclusive content.

Subscribe to our FREE newsletter and receive valuable content every month.